Empirical Finance’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $4.01M | Buy |
9,006
+60
| +0.7% | +$26.7K | 0.21% | 101 |
|
|
2025
Q1 | $4.34M | Buy |
8,946
+133
| +2% | +$64.5K | 0.26% | 86 |
|
|
2024
Q4 | $3.55M | Sell |
8,813
-103
| -1% | -$41.5K | 0.21% | 94 |
|
|
2024
Q3 | $4.15M | Buy |
8,916
+190
| +2% | +$88.4K | 0.24% | 81 |
|
|
2024
Q2 | $4.09M | Sell |
8,726
-606
| -6% | -$284K | 0.26% | 79 |
|
|
2024
Q1 | $3.9M | Buy |
9,332
+314
| +3% | +$131K | 0.24% | 89 |
|
|
2023
Q4 | $3.67M | Buy |
9,018
+48
| +0.5% | +$19.5K | 0.26% | 85 |
|
|
2023
Q3 | $3.12M | Buy |
8,970
+865
| +11% | +$301K | 0.23% | 97 |
|
|
2023
Q2 | $2.85M | Buy |
8,105
+938
| +13% | +$330K | 0.22% | 97 |
|
|
2023
Q1 | $2.26M | Buy |
7,167
+345
| +5% | +$109K | 0.21% | 101 |
|
|
2022
Q4 | $1.97M | Buy |
6,822
+545
| +9% | +$157K | 0.2% | 105 |
|
|
2022
Q3 | $1.82M | Buy |
6,277
+1,032
| +20% | +$299K | 0.22% | 93 |
|
|
2022
Q2 | $1.48M | Buy |
5,245
+273
| +5% | +$76.9K | 0.19% | 102 |
|
|
2022
Q1 | $1.3M | Buy |
4,972
+530
| +12% | +$138K | 0.15% | 130 |
|
|
2021
Q4 | $975K | Buy |
4,442
+1,179
| +36% | +$259K | 0.12% | 158 |
|
|
2021
Q3 | $592K | Buy |
3,263
+186
| +6% | +$33.7K | 0.09% | 226 |
|
|
2021
Q2 | $620K | Buy |
3,077
+428
| +16% | +$86.2K | 0.1% | 218 |
|
|
2021
Q1 | $626K | Hold |
2,649
| – | – | 0.11% | 180 |
|
|
2020
Q4 | $626K | Buy |
2,649
+466
| +21% | +$110K | 0.11% | 180 |
|
|
2020
Q3 | $594K | Buy |
2,183
+485
| +29% | +$132K | 0.13% | 155 |
|
|
2020
Q2 | $493K | Buy |
1,698
+216
| +15% | +$62.7K | 0.13% | 145 |
|
|
2020
Q1 | $353K | Buy |
1,482
+533
| +56% | +$127K | 0.11% | 147 |
|
|
2019
Q4 | $208K | Buy |
+949
| New | +$208K | 0.05% | 199 |
|
|
2017
Q1 | – | Sell |
-104
| Closed | -$8K | – | 560 |
|
|
2016
Q4 | $8K | Buy |
+104
| New | +$8K | 0.01% | 438 |
|